The Nasdaq Biotechnology Index rose more than 3%, outperforming the broader U.S. stock market. Monte Rosa Therapeutics led the gains, up 45.41%; Erasca rose 42.15%; Ventyx Biosciences increased by 36.62%. Revolution Med, GH Research, Neumora Therapeutics, Immuneering, and Tango Therapeutics saw gains between 22.21% and 28.63%. Ironwood Pharmaceuticals fell 5.30%, Gossamer Bio dropped 5.86%, and Arrowhead Pharmaceuticals decreased by 7.23%Wallstreetcn·Jan 7, 2026 at 09:40 PMERAS-2.85%VTYX0.00%
Eli Lilly is close to reaching an agreement to acquire the biotech company Ventyx for $14 per share. (The Wall Street Journal)Wallstreetcn·Jan 7, 2026 at 02:38 PMVTYX0.00%
